IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co ...

The microbial ecosystems within our mouths may affect our cognitive function as we age, according to a study. Interventions such as prebiotics, including dietary nitrate, have potential for delaying ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.